Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
- 17 May 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 100 (3), 255-262
- https://doi.org/10.1007/s10549-006-9254-4
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide StudyJournal of Clinical Oncology, 2004
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community PracticesJournal of Clinical Oncology, 2003
- Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical TrialsJournal of the National Comprehensive Cancer Network, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?European Journal of Cancer, 2000
- Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancerEuropean Journal of Cancer, 2000
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upThe New England Journal of Medicine, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaThe New England Journal of Medicine, 1994